Tiffany Y Lin1,2,3, Jasmine Hanna1,2,3, Waguih William Ishak1,2,3. 1. Drs. Lin and Ishak are with the David Geffen School of Medicine at UCLA in Los Angeles, California. 2. Dr. Ishak is also with the Department of Psychiatry & Behavioral Neurosciences at Cedars-Sinai Medical Center in Los Angeles, California. 3. Ms. Hanna is a BA candidate at the University of California in Los Angeles, California.
Abstract
Objective: Psychiatric symptoms are frequently comorbid with Cushing's syndrome (CS), a relatively rare condition that results from chronic hypercortisolism. Psychiatric manifestations might be present in the prodromal phase, during the course of the illness, and even after the resolution of CS. Our goals are to review the prevalence of psychiatric symptoms in CS; to determine the impact of psychiatric symptoms on morbidity, functioning, and quality of life; and to analyze the impact of treatment of CS on psychiatric symptoms. Methods: A systematic search of the literature database was conducted according to predefined criteria. Two authors independently conducted a focused analysis of the full-text articles and reached a consensus on 17 articles to be included in this review. Results: Overall, studies suggested that psychiatric symptoms-including, most prominently, depression-were present in a significant proportion of patients with CS. They reported lower health-related quality of life, which persisted even following the resolution of hypercortisolism. Though treatment and cure of CS significantly improved psychiatric symptoms, some patients did not achieve complete resolution of psychiatric symptoms and required continued psychiatric treatment. Conclusion: The majority of the literature indicates that psychiatric manifestations are an important part of CS and overall lower health-related quality of life and psychiatric symptoms can persist even after the cure of CS. This emphasizes the significance of early diagnosis for psychiatric management and stresses the importance of monitoring the long-term effects of neurocognitive and psychiatric symptoms and its impact on the quality of life, even after hypercortisolism resolution.
Objective: Psychiatric symptoms are frequently comorbid with Cushing's syndrome (CS), a relatively rare condition that results from chronic hypercortisolism. Psychiatric manifestations might be present in the prodromal phase, during the course of the illness, and even after the resolution of CS. Our goals are to review the prevalence of psychiatric symptoms in CS; to determine the impact of psychiatric symptoms on morbidity, functioning, and quality of life; and to analyze the impact of treatment of CS on psychiatric symptoms. Methods: A systematic search of the literature database was conducted according to predefined criteria. Two authors independently conducted a focused analysis of the full-text articles and reached a consensus on 17 articles to be included in this review. Results: Overall, studies suggested that psychiatric symptoms-including, most prominently, depression-were present in a significant proportion of patients with CS. They reported lower health-related quality of life, which persisted even following the resolution of hypercortisolism. Though treatment and cure of CS significantly improved psychiatric symptoms, some patients did not achieve complete resolution of psychiatric symptoms and required continued psychiatric treatment. Conclusion: The majority of the literature indicates that psychiatric manifestations are an important part of CS and overall lower health-related quality of life and psychiatric symptoms can persist even after the cure of CS. This emphasizes the significance of early diagnosis for psychiatric management and stresses the importance of monitoring the long-term effects of neurocognitive and psychiatric symptoms and its impact on the quality of life, even after hypercortisolism resolution.
Authors: Jitske Tiemensma; Nieke E Kokshoorn; Nienke R Biermasz; Bart-Jan S A Keijser; Moniek J E Wassenaar; Huub A M Middelkoop; Alberto M Pereira; Johannes A Romijn Journal: J Clin Endocrinol Metab Date: 2010-04-06 Impact factor: 5.958
Authors: F Castinetti; M Fassnacht; S Johanssen; M Terzolo; P Bouchard; P Chanson; C Do Cao; I Morange; A Picó; S Ouzounian; J Young; S Hahner; T Brue; B Allolio; B Conte-Devolx Journal: Eur J Endocrinol Date: 2009-03-16 Impact factor: 6.664
Authors: L D Dorn; E S Burgess; B Dubbert; S E Simpson; T Friedman; M Kling; P W Gold; G P Chrousos Journal: Clin Endocrinol (Oxf) Date: 1995-10 Impact factor: 3.478
Authors: Maureen Rakovec; William Zhu; Adham M Khalafallah; Roberto Salvatori; Amir H Hamrahian; Gary L Gallia; Masaru Ishii; Nyall R London; Murugappan Ramanathan; Nicholas R Rowan; Debraj Mukherjee Journal: Endocrine Date: 2022-10-13 Impact factor: 3.925
Authors: Victor A D Holanda; Matheus C Oliveira; Edilson D Da Silva Junior; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli Journal: Neurobiol Stress Date: 2020-10-05
Authors: Jorge Miguel Amaya; Eva M G Viho; Hetty C M Sips; Reshma A Lalai; Isabelle Sahut-Barnola; Typhanie Dumontet; Nathanaëlle Montanier; Alberto M Pereira; Antoine Martinez; Onno C Meijer Journal: J Neuroendocrinol Date: 2022-04-01 Impact factor: 3.870
Authors: Simone Daugaard Hemmingsen; Nikolai Arndal Jensen; Pia Veldt Larsen; Jan Magnus Sjögren; Mia Beck Lichtenstein; René Klinkby Støving Journal: Front Psychiatry Date: 2022-07-12 Impact factor: 5.435